KLK3 and posterior cortical atrophy: The STHLM3 model is a clinical tool for diagnosis according to the individual risk that mixes plasma biomarkers, such as PSA, free PSA, intact PSA, 232 genetic polymorphism sites, and some clinical variables (e.g., age, disease and family history, a prior biopsy of the prostate, and prostate examination), with a higher accuracy (AUC = 0.74) than other tools in the identification of GS ≥ 7 high-risk PCa [15].